London
· Delayed Price · Currency is GBP · Price in USD BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of GBP 18.74 billion. The enterprise value is 5.91 billion.
| Market Cap | 18.74B |
| Enterprise Value | 5.91B |
Important Dates
The next estimated earnings date is Monday, May 5, 2025.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.95% |
| Shares Change (QoQ) | -1.75% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 92.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.24 |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 109.13 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.74 |
| EV / Sales | 2.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -90.69 |
Financial Position
The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.45 |
| Quick Ratio | 7.26 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.23 |
| Interest Coverage | -102.02 |
Financial Efficiency
Return on equity (ROE) is -3.36% and return on invested capital (ROIC) is -4.00%.
| Return on Equity (ROE) | -3.36% |
| Return on Assets (ROA) | -3.53% |
| Return on Invested Capital (ROIC) | -4.00% |
| Return on Capital Employed (ROCE) | -6.43% |
| Revenue Per Employee | 335,953 |
| Profits Per Employee | -81,244 |
| Employee Count | 6,772 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 1.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.02% in the last 52 weeks. The beta is 1.08, so BioNTech SE's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +20.02% |
| 50-Day Moving Average | 102.70 |
| 200-Day Moving Average | 106.87 |
| Relative Strength Index (RSI) | 52.77 |
| Average Volume (20 Days) | 2,966 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.02 |
Income Statement
In the last 12 months, BioNTech SE had revenue of GBP 2.28 billion and -550.18 million in losses. Loss per share was -2.29.
| Revenue | 2.28B |
| Gross Profit | 1.83B |
| Operating Income | -1.06B |
| Pretax Income | -560.44M |
| Net Income | -550.18M |
| EBITDA | -854.34M |
| EBIT | -1.06B |
| Loss Per Share | -2.29 |
Balance Sheet
The company has 13.88 billion in cash and 210.22 million in debt, giving a net cash position of 13.67 billion.
| Cash & Cash Equivalents | 13.88B |
| Total Debt | 210.22M |
| Net Cash | 13.67B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 16.05B |
| Book Value Per Share | 66.89 |
| Working Capital | 13.46B |
Cash Flow
In the last 12 months, operating cash flow was 171.76 million and capital expenditures -236.93 million, giving a free cash flow of -65.17 million.
| Operating Cash Flow | 171.76M |
| Capital Expenditures | -236.93M |
| Free Cash Flow | -65.17M |
| FCF Per Share | n/a |
Margins
Gross margin is 80.32%, with operating and profit margins of -46.73% and -24.18%.
| Gross Margin | 80.32% |
| Operating Margin | -46.73% |
| Pretax Margin | -24.63% |
| Profit Margin | -24.18% |
| EBITDA Margin | -37.55% |
| EBIT Margin | -46.73% |
| FCF Margin | n/a |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.95% |
| Shareholder Yield | 0.95% |
| Earnings Yield | -2.94% |
| FCF Yield | -0.35% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 6.17.
| Altman Z-Score | 6.17 |
| Piotroski F-Score | n/a |